MAP kinase

MAP kinase

Any of a family of serine/threonine protein kinases belonging to the CMGC (CDK/MAPK/GSK3/CLK) kinase group, which are involved in cellular responses to various stimuli (e.g., mitogens, osmotic stress, heat shock and cytokines) and regulate cell growth, cycling, differentiation, mitosis and apoptosis.
References in periodicals archive ?
DEP-evoked formation of phospho-ERK1/2 and its subsequent transfer to the nucleus depends on RAS-RAF-MEK-ERK l/2 MAP kinase signaling and [beta]-arrestins.
Studies of MAP kinase and Nf-kB activation with comparison with the Fn-f, suggested that HA-fs activated Erk1/2, p38 and JNK much more weakly and much more slowly and in some cases required 8 hours as compared with 1 hour for Fn-f, consistent with the possibility that HA-fs activate kinases only indirectly.
Four partnered programs are in active clinical trials: a CXCR2 antagonist for chronic obstructive pulmonary disease, p38 MAP kinase inhibitors for rheumatoid arthritis, an enzyme inhibitor for oncology and a candidate for metabolic diseases.
ARRY-797 is a selective, orally active inhibitor of p38 MAP kinase and has demonstrated good tolerability and significant efficacy in preclinical models of human, the company said.
Proteins were extracted from these cells and assays were run to test the effect of the ECM and IGF-1 on fibroblasts by quantitating proteins for MAP kinase and Akt.
And this raises the dazzling possibility that a class of drugs now in development--the p38 MAP kinase inhibitors--could play a role in the treatment of each of the diseases in this eclectic group, Dr.
Collman's group has also observed that chemokines such as macrophage-inflammatory protein- 1[beta] (M1P- 1[beta]) and macrophage chemoattractant protein-1 (MCP1) are secreted by macrophages in response to gp120, and that secretion of these inflammatory factors is dependent on MAP kinase activation.
They discovered that the enzyme, called mitogen-activated protein kinase, or MAP kinase, is five to 20 times more abundant in cancerous breast cells than in noncancerous breast cells.
DeBernardo and colleagues reported that CCRCs had fewer mutations in the mammalian target of rapamycin (mTOR) pathway (PIK3CA: 25% in CCUC, 40% in CCOC, 4% in CCRC) and the MAP kinase (MAPK) pathway (KRAS: 14%, 11% and 0%, respectively).
The MAP kinase extracellular regulated kinase (ERK)1/2 activates the activator protein (AP)-1 transcription factor through phosphorylation of c-fos that can then dimerize with c-jun and bind to the AP-1 DNA binding site (Gilley et al.
When the appropriate growth factor receptor is stimulated Erk is activated in the MAP Kinase pathway.